While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines. Zepbound won on ...

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

These GLP-1 drugs have proven effective at helping people lose weight—and are showing promise for a host of other indications ...

The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

As WeightWatchers files for bankruptcy in the US, Slimming World managing director, Lisa Salmon, says weight loss injections ...

Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.

Bad reactions to popular weight-loss drugs, including Ozempic and Wegovy, are on track to soar by more than 350 per cent ...